Biopharmx Corp (BPMX) Sees Large Increase in Short Interest
Biopharmx Corp (NYSEAMERICAN:BPMX) saw a large increase in short interest in January. As of January 31st, there was short interest totalling 7,863,810 shares, an increase of 29.8% from the January 12th total of 6,056,385 shares. Currently, 7.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,965,603 shares, the days-to-cover ratio is currently 0.9 days.
In other Biopharmx news, Director Stephen Morlock acquired 330,000 shares of the company’s stock in a transaction dated Friday, November 24th. The stock was bought at an average price of $0.15 per share, for a total transaction of $49,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Shares of Biopharmx (BPMX) remained flat at $$0.18 during mid-day trading on Friday. 8,203,840 shares of the company’s stock traded hands, compared to its average volume of 11,666,780. Biopharmx has a twelve month low of $0.10 and a twelve month high of $0.90. The company has a market cap of $25.50, a price-to-earnings ratio of -0.67 and a beta of 1.40.
Separately, Maxim Group restated a “buy” rating and issued a $1.50 price objective on shares of Biopharmx in a research note on Friday, December 8th.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.